Compare Enveric Biosciences Inc (ENVB) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs LYFT Inc — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while LYFT Inc trades at $15.92 (market cap $6.17B). The key difference: LYFT Inc is far larger — about 1159.8× Enveric Biosciences Inc's market cap, and LYFT Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | LYFT | |
|---|---|---|
Market Cap | $5.32M | $6.17B |
Sector | Health | Industrials |
52-Week High | $17.40 | $24.57 |
52-Week Low | $1.28 | $12.65 |
Enterprise Value | $408.82K | $5.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Lyft trades at $16.015, up 2.59% today, with a bullish technical signal and strong cash flow growth. The stock shows robust revenue expansion to $6.32B in 2025 and a net income surge to $2.84B, though recent EPS misses in Q1 2026 raise caution. Positive sentiment is driven by strategic hires and operational efficiency gains, while analyst consensus targets $17.86 with 37% buy ratings.
Lyft's outlook is supported by improving profitability and liquidity, but faces risks from competitive pricing pressures and autonomous vehicle integration challenges. The stock offers potential upside to consensus targets, yet investors must weigh execution risks against attractive valuation multiples like a P/E of 2.38.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
